Accelerate Drug Discovery with Verified Molecular Docking
BioPrime v4.0 "Golden" is a physics-based molecular docking platform featuring a 25-dimensional feature set (16 inherited + 9 new) and a novel Three-Phase Funnelization approach: Neighborhood (burial scoring + H-bond networks), Key-in-Lock (pivot residue identification + steric gating with 80% pivot kill rate), and Gasket (induced fit + desolvation penalty). Validated against 10 targets — HIV Protease, SARS-CoV-2 Mpro, Thrombin, EGFR, CDK2, p38 MAPK, Beta-2 Adrenergic, Adenosine A2A, Estrogen Receptor, and RXR — with R² = 0.73 correlation to experimental binding affinities. Supports DePIN distributed worker nodes and BSV blockchain anchoring for immutable proof of computation.

25-dimensional scoring across Neighborhood → Key-in-Lock → Gasket progressive refinement with burial depth, H-bond networks, and desolvation penalties
Validated across 10 targets: HIV Protease, SARS-CoV-2 Mpro, Thrombin, EGFR, CDK2, p38 MAPK, Beta-2 Adrenergic, Adenosine A2A, Estrogen Receptor, RXR
Automatic identification of critical binding site residues with 80% pivot kill rate for efficient screening
Conformational flexibility with desolvation penalty calculations
Immutable proof of computation for every docking run, enabling reproducible and verifiable drug discovery
Distributed worker architecture for decentralized high-throughput molecular screening
Published research connected to this product.
45% accuracy improvement over previous generation, validated across 10 drug targets. Every docking result blockchain-verified for regulatory compliance and reproducibility.